Observational studyEpilepsia2026
Characteristics, therapeutic pathway and the economic burden of patients with drug-resistant epilepsy: A real-world analysis following the introduction of cenobamate in Italy.
Observational study in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
objectivesDrug-resistant epilepsy (DRE) remains a major clinical challenge, affecting approximately one-third of patients with epilepsy. Cenobamate, a novel antiseizure medication (ASM) approved in Italy in 2022, has shown promise in clinical trials. However, real-world data on its use, especially economic evaluations, remain limited. This analysis assessed the impact of cenobamate in Italian clinical practice, focusing on demographics, clinical traits, treatment patterns, health care use, and costs among patients with focal epilepsy treated or potentially eligible for cenobamate.
methodsA retrospective observational study was conducted using administrative health care databases covering ~12 million individuals. Adult patients with focal epilepsy were identified and stratified into three groups: (1) overall focal epilepsy population, (2) DRE patients treated with cenobamate, and (3) DRE patients potentially eligible but untreated with cenobamate. Data on demographics, comorbidities, drug utilization, health care resource use, and direct costs were analyzed. Generalized linear models (GLMs) were used to identify predictors of health care and hospitalization costs.
resultsAmong 3950 patients with focal epilepsy, 1577 (41%) had DRE. Cenobamate-treated patients were younger (mean age 42.6 vs 52.8 years) and had fewer comorbidities. Early adoption trends showed patients starting cenobamate after fewer previous treatments. Cenobamate was associated with a reduction in polypharmacy and lower hospitalization rates and specialist visits. Treatment persistence at 12 months was higher in the cenobamate group (69.6% vs 49.3%). Despite slightly higher overall health care costs (+€916, p < .05), cenobamate significantly reduced hospitalization costs (-€679, p < .05). SIGNIFICANCE: This real-world study highlights a progressively earlier adoption of cenobamate in Italy over the last few years, with patients starting after fewer prior treatments. Compared to patients potentially eligible but untreated with cenobamate, those receiving cenobamate showed greater treatment persistence, reduced polypharmacy, fewer hospitalizations, and fewer neurological visits. Despite higher drug costs, overall health care efficiency improved, supporting its potential as an effective earlier-line option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.